Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.156
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Pcn181 - Cost-Utility Analysis of Adjuvant Pertuzumab-Based Regimen in Women With Her2-Positive Breast Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy